Table 1.
Demographic and laboratory data
| N = 1079 | GD | HT |
|---|---|---|
| n (%) | 357 (33) | 722 (67) |
| Female, n (%) | 276 (77) | 598 (83) |
| Age (years) | 47·9 (34·5–56) | 35·6 (17·4–49) |
| Children, n (< 18 years) | 14 (4) | 189 (26) |
| Adults, n (> 18 years) | 343 (96) | 533 (74) |
| Duration of AITD (years) | 2 (1–5) | 2 (0·1–8) |
| TAO, n (%) | 229 (64) | 44 (6) |
| TSH (0·4–4·9 mU/l) | 1·6 (0·01–4·7) | 2·0 (1–4) |
| fT3 (1·7–3·7 pg/ml) | 4·7 (3·7–5) | 3·0 (2·6–3·5) |
| fT4 (0·7–1·5 ng/dl) | 2·0 (1·2–16·2) | 1·2 (1–1·4) |
| Tg‐Ab (< 4·1 IU/ml) | 8·4 (1·8–58) | 58·4 (10–295) |
| TPO‐Ab (< 6 IU/ml) | 93 (7–519) | 182 (38–537) |
Values are represented in median and 25 and 75 quartiles [interquartile range (IQR)]. The normal range is shown for the thyroid‐related hormones and autoantibodies. GD = Graves' disease; HT = Hashimoto's thyroiditis; AITD = autoimmune thyroid disease; TAO = thyroid‐associated orbitopathy; TPO = thyroperoxidase; Ab = antibody; fT3 = free triiodothyronine; fT4 = free thyroxine.